Abstract
Changes in an organism’s environment, genome, or gene expression patterns can lead to changes in its metabolism. The metabolic phenotype can be under selection and contributes to adaptation. However, the networked and convoluted nature of an organism’s metabolism makes relating mutations, metabolic changes, and effects on fitness challenging. To overcome this challenge, we use the Long-Term Evolution Experiment (LTEE) with E. coli as a model to understand how mutations can eventually affect metabolism and perhaps fitness. We used mass-spectrometry to broadly survey the metabolomes of the ancestral strains and all 12 evolved lines. We combined this metabolic data with mutation and expression data to suggest how mutations that alter specific reaction pathways, such as the biosynthesis of nicotinamide adenine dinucleotide, might increase fitness in the system. Our work provides a better understanding of how mutations might affect fitness through the metabolic changes in the LTEE and thus provides a major step in developing a complete genotype-phenotype map for this experimental system.
2. Introduction
Adaptation is the process by which organisms become fitter for the environment in which they live. While rooted in genetic changes, adaptive evolution can be studied at many levels of molecular and organismal phenotypes [1]. An organism’s metabolism is one of the fundamental molecular phenotypes supporting its life. It is no surprise, then, that adaptive evolution can proceed through changes in metabolism. Studies have found evidence of adaptation by comparing the metabolomes of closely related organisms. An analysis of metabolic differences between species of Drosophila found that these differences can affect lifespan and are sex-specific [2]. In prokaryotes, studies suggest that the genes involved in secondary metabolite production evolve quickly and produce large varieties of phenotypes. For example, strains of Pseudomonas aeruginosa that can produces surfactants can better mitigate oxidative stress compared to those that cannot [3]. E. coli have been shown to evolve repeatable metabolic changes when grown under selection to increase their biomass production and metabolism is often targeted for directed evolution when engineering organisms for industrial uses [4]. E. coli have also been shown produce coexisting subclones that occupy particular metabolic niches in a lab setting [5]. Despite these natural and laboratory-based examples, relating genetic, metabolic, and fitness changes is challenging because complete sets of molecular data are often unavailable.
Laboratory evolution experiments provide ample opportunities to study metabolic evolution. The Long-Term Evolution Experiment (LTEE) is an experimental evolution system where 12 replicate populations of E. coli (designated as Ara+1:6 and Ara-1:6, hereafter referred to as A-1:6 and A+1:6) are propagated in a carbon-limited medium with a 24-hour serial transfer regime [6]. Begun in 1988, the LTEE populations have evolved for more than 75,000 generations, making it the longest-running experiment of its kind. Over time, all 12 populations have continued to adapt to this environment. For example, relative fitness (measured as growth rate relative to the ancestral strain) has increased in parallel across the 12 populations [7]. Cellular size in each population has also increased [8, 9]. Parallel genomic changes in the LTEE are well characterized, and while some genes are commonly mutated across the replicate populations, most mutations are unique to each line [10–13]. Despite the variability at the genetic level, the evolved populations display similar gene expression profiles [14, 15]. In principle, mutations and changes to gene expression could affect the proteome by altering the function of a protein, the amount of protein produced, or the conditions under which it is translated. Because proteins are the biological catalysts for cellular chemistry, mutations and gene expression changes may affect the metabolome. In the LTEE, several examples of metabolic changes have been documented. The A-3 population has uniquely evolved the ability to metabolize citrate under aerobic conditions [16, 17] and A-2 has produced unique, coexisting ecotypes [18–20]. These ecotypes exhibit growth-phase dependent frequencies and differ in their ability to metabolize acetate, with one ecotype (the L ecotype) specializing on glucose and the other (the S ecotype) on acetate. The transposable-element induced loss of the rbs operon occurred early and prevents the evolved lines from growing solely on ribose [21]. Reduced ability to grow on maltose has occurred through other mechanisms [22–24]. Despite glucose being the only source of carbon provided, significant changes in the ability to grow on other carbon sources have occurred [25]. In particular, the mutator lines exhibit reduced performance on carbon sources other than glucose. The evolved lines have increased rates of glucose uptake as well as altered flux through some central carbon metabolism pathways [26].
While specific examples of how genetic changes result in metabolic changes in the LTEE (citrate, acetate, maltose, ribose) exist, a more general survey of the metabolome is lacking. Such a survey would allow a better understanding of the effects of genetic and expression changes on metabolism and provide the ability to test hypotheses from previous data. By integrating genomic [10], expression [15], and metabolic datasets, we can relate mutations to expression changes and their effects at the metabolic level. We provide ample evidence for hypotheses that specific genetic changes may exert their fitness-altering effects by changing gene expression and, ultimately, metabolism.
3. Results
3.1. Survey of metabolic changes in the LTEE
We used liquid chromatography coupled mass-spectrometry (LC/MS) to scan a broad mass range using both positive and negative ionization modes to survey the metabolomes of both ancestral strains and clones from each of the 12 evolved lines of the LTEE at 50,000 generations. We sampled two time points, 2 and 24 hours, to represent exponential and stationary phase samples, each with two biological replicates. It is important to note that the 2 hour time point captures the evolved lines, including A-3, during their growth on glucose. Additionally, the evolved lines reach stationary phase after about 4 hours of growth, with A-3 experiencing growth that levels off slowly over around 14 hours [27]. At our 24 hour time point, the evolved lines (except A-3) have been in stationary phase for around 20 hours. The differences between the early, mid, and late stationary phases are unknown. Metabolite abundances were estimated using normalized peak areas relative to standards as described in the Data processing and description. Many metabolites are detected in both ionization modes, making it unclear which mode most accurately represents the abundance of the compound in a sample. As a result, we used the combination of a compound and the ionization mode it was detected in as a feature of the data.
We begin by surveying the data in a metabolome-wide manner. Because E. coli exhibits large physiological differences across growth phases [28–30], we expected comparisons within a growth phase to be more similar than comparisons across growth-phases. Indeed, the distribution of within growth phase correlations of metabolite abundances is higher than the distribution of across growth-phase correlations (Fig. S1A). Because growth-specific differences have the potential to drown out signals of adaptation, we performed all subsequent analyses in a growth phase-specific manner.
To identify large scale differences in metabolite abundances, we performed a principal component analysis (PCA) of metabolite abundances in a phase-specific manner. In the exponential phase, the PCA strongly separates A-3 from the other samples (Fig. 1A). This is possibly due to the unique ability of A-3 to metabolize citrate. Citrate is present in the medium because it was originally added as a chelating agent. However, mutations in A-3 have allowed it to metabolize citrate under aerobic conditions, giving it access to additional carbon that the other lines do not have [16, 31]. Half of the evolved lines have a mutator phenotype and have at least an order of magnitude higher number of fixed point mutations than the non-mutators [10]. Despite the large differences in the number of mutations that have accumulated, we do not observe a strong effect of mutator status on the separation between evolved lines in the PCA. This is consistent with previous observations of a minimal effect of mutator status on changes in gene-expression patterns [15]. The first two principal components are dominated by contributions of nucleoside monophosphates, amino acids, and compounds involved in carbon metabolism, such as glucose and succinate (Fig. S3A-B).
Figure 1.
(A-B) Principal component analysis based on log10(mean normalized peak area) separated by growth phase. R06 and R07 are the ancestors (REL606 and REL607). For this figure, the combination of ionization mode and metabolite was treated as a feature of the data. (C) Pairwise Spearman’s correlations based on log2(fold – change) relative to the ancestor. The black boxes and points indicate the observed correlations, the grey boxes indicate correlations calculated after 100,000 randomizations of fold-changes within each line. p-values indicate the results of a two-tailed t-test between the observed and expected distributions. **** indicates a p-value ≤ 0.0001. (D-E) The observed correlations from C plotted in a network manner. D is the exponential phase and E is the stationary phase. Lines are clustered based on similarity and the color of the line connecting two points indicates the strength of the correlation.
Similar to the exponential phase, A-3 separates from the rest of the evolved lines in a PCA of metabolites in the stationary phase (Fig. 1B). The primary driver of variation in the first principal component (PC1) is the relative abundances of compounds in A-3 (Fig. S4A). In addition to A-3, A-2 also shows a higher degree of separation from the other lines. Though this experiment was performed with single clones, the 12 flasks in the LTEE are not isoclonal but instead consist of competing subclones that sometimes coexist for extended periods [12]. A-2 is the best-understood example, consisting of two major subclones, L and S [18–20]. The observed separation might be because the A-2 clone in this experiment comes from the L ecotype, which does not grow as well on acetate compared to the other lines. In contrast to exponential phase PCA, mutator status appears to be a driving factor of PC2 in the stationary phase (Fig. S4A-B) with mutator lines having lower abundances of nucleoside monophosphates relative to non-mutators during stationary phase. What this is indicative of is unclear.
A common theme in studies of LTEE is the high degree of parallelism observed at the genetic [10], gene expression [15], and fitness levels [32]. For example, genes involved in flagellar biosynthesis and amino acid metabolism are commonly mutated across the evolved lines [10] with associated changes in expression levels [15]. To examine the extent of parallel changes in metabolites, we calculated the ratio of the peak area in an evolved line to the peak area in the ancestor for each compound after averaging biological replicates. Pairwise Spearman’s correlations using these ratios are significantly higher than expected when comparing the observed distribution to a distribution generated by randomizing fold-changes within a sample prior to calculating correlations (Fig. 1C, p < 0.001, t-test). In the exponential phase, the lowest correlations were mainly between a pair involving one of A-2, A-4, or A-6, and another evolved line (Fig. 1D). The correlations of metabolite abundances across evolved lines are more similar in the exponential phase (Fig. 1D) than in the stationary phase (Fig. 1E) (t-test comparing the observed exponential and stationary phase correlations in Fig. 1C, p < 0.001). It may be that the strategies of metabolite usage and abundance in the rapidly growing exponential phase are more similar across lines than the strategies of survival are in the stationary phase or that there is less selection on the metabolome during the stationary phase. Further studies would be required to understand this phenomenon.
To further quantify the extent of shared changes, we considered the difference between the number of shared changes that were observed and expected to be observed by chance. We approximated an expected distribution of shared changes using a Sum of Independent Non-Identical Binomial Random Variables (SINIB) method [33], essentially asking what the chance of repeatedly observing the same change in an increasing number of evolved lines is. For more details on this method, see section 5.1.5. For metabolic features (the combination of a compound and the ionization mode it was detected in) that shared alterations in only a few lines (generally six or less), we cannot suggest selection on these changes because we see fewer or as many changes as expected (Fig. S5, Fig. S6). These may represent metabolites that negatively affect fitness when altered. On the other hand, we observe more changes shared in a higher number of evolved lines than expected. These shared changes may be beneficial, but this would need to be clarified by additional experiments. By combining genomic, expression, and metabolic datasets, we can better explore the nature of these changes and how they may impact fitness.
3.2. Increased NAD may facilitate higher energy demands during adaptation
In the LTEE, mutations to the nadR gene have occurred in all of the evolved lines and appear to have been under strong selection to improve fitness [10, 34]. NadR is a dual-function protein that negatively regulates genes involved in the synthesis of nicotinamide adenine dinucleotide (NAD) and has its own kinase activity [35, 36].
NAD and its phosphorylated derivative NADP function as electron carriers and are necessary for many catabolic and anabolic pathways in the cell. While untested, hypotheses for how nadR mutations might increase fitness involve derepression of its target genes and increases to intracellular NAD; this may aid in shortening the lag phase and modulating redox chemistry [34, 38, 39]. The abundance of NAD and related compounds in a cell can modulate reaction rates and other processes [36, 40]. We had previously shown that mutations in nadR in the evolved lines lead to consistent upregulation of its target genes [15] (Fig. 2). Here we test if there are higher abundances of NAD and NAD-related metabolites in the evolved lines consistent with changes observed at the genetic and gene expression levels.
Figure 2.
Depiction of three pathways (bold-faced text) that contribute to NAD abundances in the cell. Graphics and pathway names are adapted from the EcoCyc database [37]. All data represents exponential phase measurements. Genes that code for enzymes are shown in purple and metabolites in green. Heatmaps positioned to the right of gene names show the fold-change in expression relative to the ancestor (data from [15]). Grey spaces (also marked with an X) in gene expression heatmaps represent evolved lines where that gene contains an indel or is deleted. Asterisks indicate genes that are transcriptionally regulated by NadR. Heatmaps positioned to the left of metabolite names show changes in metabolite abundance relative to the ancestor. PnuC transports compounds into the cell. Each heatmap represents one ionization mode, but a mixture of positive and negative ionization mode data is shown depending on which mode a compound was detected. See Fig. S7 for complete data.
The genes regulated by NadR participate in specific reactions along NAD synthesis pathways. We detected some of the compounds in these pathways as well as both oxidized and reduced forms of NAD and NADP (Fig. 2). Compared to the ancestors, both redox states of NAD and NADP are almost universally increased in the evolved lines during the exponential phase (Fig. 2, Fig. S7), with median fold-changes of 3.32 and 4.65 for NAD and NADH, respectively. NADP is generated through phosphorylation of NAD by NadK [36, 41] and saw median fold-changes of 2.34 and 3.54 for NADP and NADPH, respectively. Because NADP is generated from NAD, and each exists in two oxidation states, we expected all four compounds to see similar increases within an evolved line. Indeed, increases in the various redox and phosphorylation states were consistent within an evolved line (0.77 < R < 0.97, Fig. S7B). Aspartate, the starting point for NAD synthesis, was also increased in most of the evolved lines, with a median fold-change of 1.94. Nicotinamide mononucleotide, which can be used to make NAD, was consistently increased, with a median fold-change of 2.51. In the stationary phase, most of these patterns remain unchanged except for aspartate, which is generally lower in abundance compared to the ancestor (Fig. S7A, S3C). These results suggest that the end product of the mutations in nadR is increased intracellular NAD.
3.3. Derepression of Arginine biosynthesis at genetic, gene expression, and metabolic levels
Similar to nadR, another consistent target of mutations in the LTEE is a transcriptional repressor of genes involved in arginine biosynthesis argR [10]. ArgR, along with arginine, negatively autoregulates the arginine biosynthesis pathway by downregulating the participating genes when arginine is abundant [42]. As an amino acid, the primary role of arginine is in protein synthesis. However, various reactions produce and consume arginine; both its synthesis and the regulation of the enzymes involved are complex (see [43] and the EcoCyc [37] pathway ”superpathway of arginine and polyamine biosynthesis”). For example, arginine can be a source of nitrogen and carbon or be used for ATP synthesis [44]. Because of these complications, if mutations in argR and the subsequent changes in gene expression do affect this pathway, it is unclear at which step one might observe a change or if that change might be in a different pathway.
Mutations in argR are localized to specific regions, potentially disrupting the DNA binding domain, the arginine sensing domain, or interaction domain, which is required for hexermerization of the protein [42]. These mutations in argR could reduce its ability to repress its target genes, resulting in their increased expression. Consistent with these expectations, we had previously observed parallel increases in the expression of genes repressed by ArgR (Fig. 3) [15].
Figure 3.
Partial depiction of the pathway ”superpathway of arginine and polyamine biosynthesis” [37]. All data represents exponential phase measurements. Genes that code for enzymes are shown in purple, and metabolites in green. Heatmaps positioned to the right of gene names show the fold-change in expression relative to the ancestor (data from [15]). Asterisks indicate genes that are transcriptionally regulated by ArgR. Heatmaps positioned near metabolite names show changes in metabolite abundance relative to the ancestor. Each heatmap represents one ionization mode, but a mixture of positive and negative ionization mode data is shown depending on which mode a compound was detected. See Fig. S8 for complete data and Fig. S9 for line specific data.
We were able to detect 11 compounds involved in the superpathway of arginine and polyamine biosynthesis (Fig. 3, Fig. S8A). Compared to the ancestor, arginine was increased in nine (negative mode) or ten (positive mode) evolved lines and experienced a median fold-change of 1.9 across both ionization modes in the exponential phase. This pattern also persisted in the stationary phase (Fig. S8A). While arginine is increased in both growth phases in most of the evolved lines, other compounds in this pathway show highly variable changes (Fig. S8A). Despite the consistent relationship between mutations, expression changes, and changes in the abundance of arginine, how this might affect fitness is not obvious. Higher intracellular abundances of amino acids could facilitate higher translation rates and promote faster growth. While we do observe that some amino acids show increases in their abundances in most evolved lines in the exponential phase (Fig. S8), further experiments would be needed to confirm if these amino acids are used in protein synthesis or in other pathways.
3.4. Functional changes in the central carbon metabolism
Low carbon availability is the key feature of the minimal medium used in the LTEE, and selection for better use of carbon is a driving force of adaptation in the system. Hence, how mutations and expression changes might affect fitness by altering central carbon metabolism pathways is of interest. The evolved lines have seen significant positive and negative changes in their ability to grow on different carbon substrates. Rather than metabolic specialization, this was found to be due to the accumulation of deleterious mutations that affect the ability to grow on other substrates [25]. Unique changes in A-3 allow it to metabolize citrate under aerobic conditions, granting it access to extra carbon from an unused ecological niche [16, 17]. The evolved lines retain more carbon in their biomass compared to the ancestors [31], and increased glucose uptake rates have been demonstrated [26]. Despite the abundance of molecular data associated with the LTEE, the highly networked nature of the genes and metabolites involved in central carbon metabolism makes relating the various molecular data to each other challenging. In particular, mass-spectrometry data alone will not allow us to differentiate between sources for compounds that are generated by many reactions. We might overcome this limitation by combining genomic, expression, and metabolic datasets.
We again sought instances of parallel sets of mutations and expression changes that may exert their effects at the metabolic level. Three genes that are key components in the glyoxylate cycle, aceB, aceA, and aceK were commonly upregulated in the evolved lines [15]. Their transcriptional regulators iclR and arcB are heavily mutated [10], and this is known to be beneficial in the LTEE [17]. The glyoxylate cycle allows the use of acetate as a carbon source by converting it to succinate, which can later be fed into the citric acid cycle [37, 45]. Because these genes had increased expression, the compounds they produce (succinate, glyoxylate, and malate) may be elevated in the evolved lines relative to the ancestor. Succinate and malate were reliably identified in our data, but glyoxylate was not. Unfortunately, acetate was part of the mobile phase of our liquid chromatography setup, thus preventing its accurate quantification. Likewise, most of the molecules in the glyoxylate cycle, including succinate and malate, are also components of the citric acid cycle and can be produced or consumed by other enzymes. Because we cannot distinguish where changes in these metabolites come from, we chose to look at compounds from central carbon metabolism in general, considering compounds from the glyoxylate cycle, glycolysis, and the citric acid cycle.
Overall, 18 compounds from these pathways are detected in our LC/MS assay. Regarding the glyoxylate shunt, malate, aconitate, and succinate were generally elevated in the evolved lines (median fold-change of 5.38, 1.66, and 2.30 respectively (Fig. 4)). Interestingly, the evolved lines appear to have similar or lower amounts of glucose despite having been shown to have increased glucose uptake rates [26]. This discrepancy is likely due to the fact that in [26], glucose uptake rates were calculated by measuring the depletion of glucose in the medium, whereas we measured glucose from inside the cells. Once inside the cell, we suspect that the glucose is quickly used. This is supported by the fact that other downstream glycolysis compounds, like phosphoenolpyruvate (PEP), are generally elevated (median fold-change of 6.72, Fig. 4).
Figure 4.
The distribution of fold-changes relative to the ancestor for compounds involved in carbon metabolism. Red and black indicate detection in positive or negative ionization mode, respectively. Not all compounds were detected in both ionization modes. Compounds are ordered from top to bottom roughly as they occur in glycolysis or other reactions.
An increase in PEP is also consistent with a hypothesis related to increased glucose uptake. It was previously noted that all of the evolved lines contain what are likely inactivating mutations in the gene pykF. pykF encodes pyruvate kinase I, one of two isozymes that generate ATP by converting PEP to pyruvate [46]. It was thought that inactivating mutations in pykF reduce the conversion of PEP to pyruvate, forcing a buildup of PEP, and that because PEP is the energy source for glucose import in the sugar-transporting phosphotransferase system, a buildup of PEP might increase glucose uptake rates. Our data, which shows increases in PEP, lends support to these hypotheses.
The citric acid cycle is a major metabolic pathway that extracts energy via the reduction of electron carriers like NAD. These electrons are shuttled to the electron transport chain by NAD, where they are used to generate ATP. NAD can be reduced at two points during the citric acid cycle, the conversion of alpha-ketoglutarate to succinate and the conversion of malate to oxaloacetate. If the citric acid cycle is running faster in the evolved lines due to their higher growth rates and hence higher energy demands, then more NAD may be required to efficiently shuttle electrons from the citric acid cycle to the electron transport chain. Interestingly, we measured a median fold-change of 3.13 for alpha-ketoglutarate and 5.38 for malate (Fig. 4). Additionally, increases in these compounds are correlated with an increase in NAD compounds within an evolved line (Fig. S10). It may be that increases in NAD allow faster operation of the citric acid cycle. However, alternative hypotheses must be considered.
Overflow metabolism appears to be common in the evolved lines. Overflow metabolism refers to the seemingly wasteful production of metabolites that do not participate in the most efficient form of ATP generation, even when glycolytic substrates and oxygen are plentiful. The Warburg effect [47] and acetate production are examples of this phenomenon in human cancers and E. coli [48] respectively. Our observation of the buildup of PEP is an example of overflow metabolism and may lend support to the hypothesis that the evolved lines are using overflow metabolism to gain access to the glycolytic intermediates and using them for other purposes, like as an energy source for sugar import. Experiments using radioactive tracers to study flux through these pathways are needed to confirm any hypotheses.
4. Discussion
The metabolome of a cell is the integration point of an organism’s environment, genetics, and gene expression patterns. Metabolism has been shown to contribute to generating adaptive phenotypes [2, 49–51]. However, how mutations affect metabolism through changes in gene expression and ultimately affect fitness is less clear. Specific examples of this have been studied in the LTEE, such as the acquisition of citrate metabolism in A-3 [16, 17]. We used metabolic mass-spectrometry to study other aspects of the LTEE, relating mutations and expression changes to metabolic changes. This allowed us to lend support to previous hypotheses of how certain mutations affect fitness in the system. For instance, we show how mutations in nadR alter the expression of its target genes and increase the intracellular abundance of NAD. It also enables new areas of investigation, such as what role mutations to argR and subsequent expression and metabolic changes might mean for the system.
A key limitation of the data presented here is that it contains measurements of 196 metabolites out of the 3755 metabolites currently annotated in the E. coli metabolome database [52]. Nonetheless, analysis of this subset of data can reveal some global patterns of metabolite changes. For example, distinct clustering of A-3 and A-2 in the PCA’s suggests that even with a limited sampling of the metabolome, the unique characteristics of these lineages are observable at the metabolic level. Interestingly, while the mutator lines do not form a well-defined group in the exponential phase, their reduced abundances of nucleoside monophosphates in the stationary phase group them together (Fig. 1B). Due to deletions of key biosynthetic genes, the mutators are less flexible than the non-mutators in their ability to grow on different carbon sources [25]. A-6, in particular, has one of the higher mutational burdens and is the least flexible in its ability to grow on different carbon substrates. Pathways with missing or broken genes may cause the shunting of those compounds to different pathways while also starving downstream reactions of the now missing reactants.
Though most studies of the LTEE focus on the activity of the evolved lines in the exponential phase, they spend most of their time in the stationary phase. Experiments studying the evolution of E. coli during long-term stationary phase (around three years of culture with no addition of resources) showed that mutations continue to accumulate during this time and that patterns suggestive of adaptive evolution had occurred [53, 54]. While our study chose the latest possible time point for examining the stationary phase (immediately before the transfer to a new flask), differences between early, mid, and late stationary phases may exist. Time course experiments with a finer resolution would reveal details about the specific nature of the stationary phase in the LTEE.
Supplementary Material
Acknowledgements
We thank Richard Lenski for generously providing clones from the LTEE. Premal Shah is supported by NIH/NIGMS grant R35 GM124976 and start-up funds from the Human Genetics Institute of New Jersey at Rutgers University. Samhita S. Yadavalli is supported by NIGMS R35 GM147566 and institutional start-up funds. Mass-spectrometry data were generated by the Rutgers Cancer Institute of New Jersey Metabolomics Shared Resource, supported in part with funding from NCI-CCSG P30CA072720-5923.
Footnotes
Competing interests
Premal Shah is a member of the Scientific Advisory Board of Trestle Biosciences and is a Director at Ananke Therapeutics. Srujana S Yadavalli consults and collaborates with Designs for Vision Inc. Kyle S. Skalenko is a scientist at Specialty Assays Inc.
References
- (1).Dobzhansky T. Am. Zool. 1964, 4, 443–452. [DOI] [PubMed] [Google Scholar]
- 2.Harrison B. R.; Hoffman J. M.; Samuelson A.; Raftery D.; Promislow D. E. L. Mol. Biol. Evol. 2021. [DOI] [PMC free article] [PubMed]
- 3.Santamaria G.; Liao C.; Lindberg C.; Chen Y.; Wang Z.; Rhee K.; Pinto F. R.; Yan J.; Xavier J. B. Elife 2022, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ibarra R. U.; Edwards J. S.; Palsson B. O. Nature 2002, 420, 186–189. [DOI] [PubMed] [Google Scholar]
- 5.Spencer C. C.; Tyerman J.; Bertrand M.; Doebeli M. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 1585–1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lenski R. E.; Rose M. R.; Simpson S. C.; Tadler S. C. Am. Nat. 1991, 138, 1315–1341 [Google Scholar]
- 7.Lenski R. E. et al. Proc. Biol. Sci. 2015, 282, 20152292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Grant N. A.; Abdel Magid A.; Franklin J.; Dufour Y.; Lenski R. E. J. Bacteriol. 2021, 203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Philippe N.; Pelosi L.; Lenski R. E.; Schneider D. J. Bacteriol. 2009, 191, 909–921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tenaillon O.; Barrick J. E.; Ribeck N.; Deatherage D. E.; Blanchard J. L.; Dasgupta A.; Wu G. C.; Wielgoss S.; Cruveiller S.; Médigue C.; Schneider D.; Lenski R. E. Nature 2016, 536, 165–170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Tenaillon O.; Rodríguez-Verdugo A.; Gaut R. L.; McDonald P.; Bennett A. F.; Long A. D.; Gaut B. S. Science 2012, 335, 457–461. [DOI] [PubMed] [Google Scholar]
- 12.Good B. H.; McDonald M. J.; Barrick J. E.; Lenski R. E.; Desai M. M. Nature 2017, 551, 45–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Limdi A.; Owen S. V.; Herren C.; Lenski R. E.; Baym M. Parallel changes in gene essentiality over 50,000 generations of evolution., en, 2022.
- 14.Cooper T. F.; Rozen D. E.; Lenski R. E. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1072–1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Favate J. S.; Liang S.; Cope A. L.; Yadavalli S. S.; Shah P. Elife 2022, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Blount Z. D.; Barrick J. E.; Davidson C. J.; Lenski R. E. Nature 2012, 489, 513–518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Quandt E. M.; Gollihar J.; Blount Z. D.; Ellington A. D.; Georgiou G.; Barrick J. E. Elife 2015, 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (18).Lenski R. E. ISME J. 2017, 11, 2181–2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (19).Plucain J.; Hindré T.; Le Gac M.; Tenaillon O.; Cruveiller S.; Médigue C.; Leiby N.; Harcombe W. R.; Marx C. J.; Lenski R. E.; Schneider D. Science 2014, 343, 1366–1369. [DOI] [PubMed] [Google Scholar]
- (20).Rozen D. E.; Lenski R. E. Am. Nat. 2000, 155, 24–35. [DOI] [PubMed] [Google Scholar]
- 21.Cooper V. S.; Schneider D.; Blot M.; Lenski R. E. J. Bacteriol. 2001, 183, 2834–2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Meyer J. R.; Agrawal A. A.; Quick R. T.; Dobias D. T.; Schneider D.; Lenski R. E. Evolution 2010, 64, 3024–3034. [DOI] [PubMed] [Google Scholar]
- 23.Pelosi L.; Kühn L.; Guetta D.; Garin J.; Geiselmann J.; Lenski R. E.; Schneider D. Genetics 2006, 173, 1851–1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Travisano M.; Vasi F.; Lenski R. E. Evolution 1995, 49, 189–200. [DOI] [PubMed] [Google Scholar]
- (25).Leiby N.; Marx C. J. PLoS Biol. 2014, 12, e1001789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Harcombe W. R.; Delaney N. F.; Leiby N.; Klitgord N.; Marx C. J. PLoS Comput. Biol. 2013, 9, e1003091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Blount Z. D.; Borland C. Z.; Lenski R. E. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7899–7906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Jaishankar J.; Srivastava P. Front. Microbiol. 2017, 8, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pletnev P.; Osterman I.; Sergiev P.; Bogdanov A.; Dontsova O. Acta Naturae 2015, 7, 22–33. [PMC free article] [PubMed] [Google Scholar]
- 30.Navarro Llorens J. M.; Tormo A.; Martínez-García E. FEMS Microbiol. Rev. 2010, 34, 476–495. [DOI] [PubMed] [Google Scholar]
- 31.Turner C. B.; Wade B. D.; Meyer J. R.; Sommerfeld B. A.; Lenski R. E. R Soc Open Sci 2017, 4, 170497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wiser M. J.; Ribeck N.; Lenski R. E. Science 2013, 342, 1364–1367. [DOI] [PubMed] [Google Scholar]
- 33.Liu B.; Quertermous T. R J. 2018, 10, 472. [Google Scholar]
- 34.Woods R.; Schneider D.; Winkworth C. L.; Riley M. A.; Lenski R. E. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 9107–9112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Begley T. P.; Kinsland C.; Mehl R. A.; Osterman A.; Dorrestein P. In Vitamins & Hormones; Academic Press: 2001; Vol. 61, pp 103–119. [DOI] [PubMed] [Google Scholar]
- 36.Osterman A. EcoSal Plus 2009, 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Keseler I. M.; Collado-Vides J.; Gama-Castro S.; Ingraham J.; Paley S.; Paulsen I. T.; Peralta-Gil M.; Karp P. D. Nucleic Acids Res. 2005, 33, D334–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Grose J. H.; Bergthorsson U.; Roth J. R. J. Bacteriol. 2005, 187, 2774–2782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Grose J. H.; Joss L.; Velick S. F.; Roth J. R. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7601–7606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Cantó C.; Menzies K. J.; Auwerx J. Cell Metab. 2015, 22, 31–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Kawai S.; Mori S.; Mukai T.; Hashimoto W.; Murata K. Eur. J. Biochem. 2001, 268, 4359–4365. [DOI] [PubMed] [Google Scholar]
- (42).Tian G.; Maas W. K. Mol. Microbiol. 1994, 13, 599–608. [DOI] [PubMed] [Google Scholar]
- 43.Charlier D.; Glansdorff N. EcoSal Plus 2004, 1. [DOI] [PubMed] [Google Scholar]
- 44.Reitzer L. EcoSal Plus 2005, 1. [DOI] [PubMed]
- 45.Cioni M.; Pinzauti G.; Vanni P. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry 1981, 70, 1–26. [Google Scholar]
- 46.Philippe N.; Crozat E.; Lenski R. E.; Schneider D. Bioessays 2007, 29, 846–860. [DOI] [PubMed] [Google Scholar]
- 47.Warburg O. Science 1956, 123, 309–314. [DOI] [PubMed] [Google Scholar]
- 48.Enjalbert B.; Millard P.; Dinclaux M.; Portais J.-C.; Létisse F. Sci. Rep. 2017, 7, 42135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Miyazawa K.; Noguchi T. J. Toxicol. Toxin Rev. 2001, 20, 11–33. [Google Scholar]
- 50.Hefetz A.; Blum M. S. Biochim. Biophys. Acta 1978, 543, 484–496. [DOI] [PubMed] [Google Scholar]
- 51.Chevrette M. G.; Gutiérrez-García K.; Selem-Mojica N.; Aguilar-Martínez C.; Yañez-Olvera A.; Ramos-Aboites H. E.; Hoskisson P. A.; Barona-Gómez F. Nat. Prod. Rep. 2020, 37, 566–599. [DOI] [PubMed] [Google Scholar]
- 52.Sajed T.; Marcu A.; Ramirez M.; Pon A.; Guo A. C.; Knox C.; Wilson M.; Grant J. R.; Djoumbou Y.; Wishart D. S. Nucleic Acids Res. 2016, 44, D495–501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Katz S.; Avrani S.; Yavneh M.; Hilau S.; Gross J.; Hershberg R. Mol. Biol. Evol. 2021, 38, 2778–2790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Ratib N. R.; Seidl F.; Ehrenreich I. M.; Finkel S. E. MBio 2021, 12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Su X.; Chiles E.; Maimouni S.; Wondisford F. E.; Zong W.-X.; Song C. Anal. Chem. 2020, 92, 4829–4837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.R Core Team R: A Language and Environment for Statistical Computing.; R Foundation for Statistical Computing, Vienna, Austria, 2022.
- 57.Wickham H. et al. JOSS 2019, 4, 1686. [Google Scholar]
- 58.Wei R.; Wang J.; Su M.; Jia E.; Chen S.; Chen T.; Ni Y. Sci. Rep. 2018, 8, 663. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.




